Asahi Kasei’s Hovilpri (approved for treating lesions caused by herpes simplex virus) received FDA approval, validating a key milestone following the company’s $919 million acquisition of AiCuris Anti-Infective Cures. The once-daily pill adds another market-ready antiviral option as clinicians manage HSV-related morbidity and recurrence risk. The approval also reflects how acquirers are monetizing late-stage assets post-deal, a pressure point for business development teams navigating timelines and regulatory execution.